Sleep-focused telehealth providers offer evidence-based supplementation and clinician-prescribed alternatives.
Reader-supported, we may earn a commission through links on this site. Rankings are editorially independent. Disclosure · Methodology
Chronic insomnia affects approximately 10–15% of adults and is associated with increased risk of cardiovascular disease, metabolic syndrome, depression, and cognitive decline. First-line treatment is Cognitive Behavioural Therapy for Insomnia (CBT-I), which has demonstrated superiority to sleep medication in long-term outcomes. Telehealth platforms increasingly offer digital CBT-I programs alongside pharmacological options.
Pharmacological sleep aids range from over-the-counter melatonin and magnesium to prescription medications including suvorexant (Belsomra), lemborexant (Dayvigo), and low-dose doxepin. Melatonin is most effective for circadian rhythm disorders (jet lag, shift work) rather than primary insomnia. Prescription orexin receptor antagonists (suvorexant, lemborexant) have a more favourable safety profile than traditional benzodiazepines and Z-drugs.
Sleep-focused telehealth is a small but growing category. Most platforms offer a combination of supplementation protocols, digital CBT-I, and prescription access where appropriate. The evidence base for telehealth-delivered CBT-I is strong — multiple RCTs demonstrate equivalence to in-person CBT-I.
Cannabinoid-based sleep aids with independent sleep-study backing.
Multi-category online men’s-health platform with ED plans from $20–$90/month and separately priced TRT care.
Sleep treatment evidence varies by intervention. CBT-I has the strongest evidence base. Prescription sleep aids are appropriate for short-term use or specific clinical situations.
| Endpoint | Finding |
|---|---|
| CBT-I vs medication (meta-analysis)1 | CBT-I superior to sleep medication for long-term insomnia outcomes; remission rates 40–60% vs 20–30% for medication |
| Digital CBT-I efficacy2 | Digital CBT-I reduces sleep onset latency by 20 minutes and improves sleep efficiency by 10% vs waitlist control |
| Melatonin for sleep onset3 | Melatonin reduces sleep onset latency by 7.1 minutes (95% CI 4.4–9.8) in meta-analysis of 19 RCTs |
| Suvorexant vs placebo4 | Suvorexant 20 mg significantly improved sleep onset and maintenance vs placebo in Phase 3 trials; no next-day impairment at approved doses |
RxNotebook is an editorial publication. Citations point to peer-reviewed journals, FDA labeling, and clinical society guidelines. We are not affiliated with the studies cited above. This page is for general information and is not medical advice.
Sleep providers are ranked by evidence quality for offered protocols, formulary breadth (CBT-I, supplementation, prescription options), pricing transparency, and Trustpilot score.
Full methodology →We use Google Analytics 4 to understand how readers find and use RxNotebook. Analytics cookies are only set with your consent. We do not use advertising cookies. See our Cookie Policy and Privacy Policy for details.